Endothelial dysfunction and hypertension

Drugs

Volumn 53, Issue SUPPL. 1, 1997, Pages 30-41

  Ferro, Charles J ^a   Webb, David J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR; NIFEDIPINE; NITRIC OXIDE; SUPEROXIDE; THIAZIDE DIURETIC AGENT; VASOACTIVE AGENT; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

AGING; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CELL ADHESION; CELL FUNCTION; CHRONIC KIDNEY FAILURE; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ENDOTHELIUM CELL; ESSENTIAL HYPERTENSION; HEART INFARCTION; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; HYPERTENSION; HYPERTROPHY; KIDNEY FAILURE; MIGRAINE; MONOCYTE; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; RESTENOSIS; SMOOTH MUSCLE FIBER; STROKE; SUBARACHNOID HEMORRHAGE; THROMBOCYTE; UNSTABLE ANGINA PECTORIS; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ANGINA;

EID: 0031040445     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199700531-00006     Document Type: Conference Paper

References (102)

1. Vanhoutte PM. Endothelium and control of cardiovascular function. Hypertension 1989; 13: 658-67
2. 2 and prostacyclin. Pharmacol Rev 1979; 30: 293-331
3. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesise nitric oxide from L-arginine. Nature 1988; 333: 664-6
4. Komatsu Y, Itoh H, Suga S, et al. Regulation of endothelial production of C-type natriuretic peptide in coculture with vascular smooth muscle cells: role of the vascular natriuretic peptide system in vascular growth inhibition. Circ Res 1996; 78: 606-14
5. Vanhoutte PM. Vascular physiology: the end of the quest? Nature 1987; 327: 459-60
6. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-5
7. Peart WS. Concepts in hypertension: the Croonian Lecture. J Coll Physicians Lond 1980; 14: 141-52
8. Vallance P, Collier J. Biology and clinical relevance of nitric oxide. BMJ 1994; 309: 453-7
9. Ferro CJ, Webb DJ. The clinical potential of endothelin receptor antagonists in cardiovascular medicine. Drugs 1996; 51: 12-27
10. Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989; 2: 998-1000
11. Haynes WG, Noon JP, Walker BR, et al. Inhibition of nitric oxide synthesis increases blood pressure in healthy humans. J Hypertens 1993; 11: 1375-80
12. Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 1994; 344: 852-4
13. Haynes WG, Ferro CJ, O'Kane KPJ, et al. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in man. Circulation 1996; 93: 1860-70
14. Lamas L, Marsden PA, Li GK, et al. Endothelial nitric oxide synthase: molecular cloning and characterisation of a distinct constitutive enzyme isoform. Proc Natl Acad Sci USA 1992; 89: 6348-52
15. Buga GM, Gold ME, Fukuto JM, et al. Shear stress-induced release of nitric oxide from endothelial cells grown on heads. Hypertension 1991; 17: 187-93
16. Weiner CP, Lizasoain I, Baylis SA, et al. Induction of calcium-dependent nitric oxide syntheses by sex hormones. Proc Natl Acad Sci USA 1994; 91: 5212-6
17. Schmidt HHHW, Zernikow B, Bachlich S, et al. Basal and stimulated formation and release of L-arginine-derived nitrogen oxides from cultured endothelial cells. J Pharmacol Exp Ther 1990; 254: 591-7
18. Cooke J, Tsao P. Is nitric oxide an endogenous antiatherogenic molecule? Arterioscler Thromb 1994; 14: 653-5
19. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83: 1774-7
20. Rees DD, Palmer RMJ, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci USA 1989; 86: 3375-8
21. Radomski MW, Palmer RMJ, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA 1990; 87: 5193-7
22. Winquist RJ, Bunting PB, Baskin EP, et al. Decreased endothelium-dependent relaxation in New Zealand genetic hypertensive rats. J Hypertens 1984; 2: 541-5
23. Wu X, Mäkynen H, Kähönen M, et al. Mesenteric arterial function in vitro in three models of experimental hypertension. J Hypertens 1996; 14: 365-72
24. Lyons D, Webster J, Benjamin N. The effect of antihypertensive therapy on responsiveness to local intra-arterial NG-monomethyl-L-arginine in patients with essential hypertension. J Hypertens 1994; 12: 1047-53
25. Panza JA, Quyyumi AA, Callahan TS, et al. Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension. J Am Coll Cardiol 1993; 21: 1145-51
26. Panza JA, Casino PR, Kilcoyne CM, et al. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 1993; 87: 1468-74
27. Taddei S, Virdis A, Mattei P, et al. Vasodilatation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993; 21 (6 Pt 2): 929-33
28. Treasure CB, Klein JL, Vita JA, et al. Hypertension and left ventricular hypertrophy are associated with impaired endothelium-dependent relaxation in human coronary resistance vessels. Circulation 1993; 7: 86-93
29. Egashira K, Suzuki S, Hirooka Y, et al. Impaired endothelium-dependent vasodilatation of large epicardial and resistance coronary arteries in patients with essential hypertension: different responses to acetylcholine and substance P. Hypertension 1995; 25: 201-6
30. Taddei S, Mattei P, Virdis A, et al. Forearm vasodilatation in response to acetylcholine is increased by potassium in essential hypertensive patients. J Hypertens 1993; 11 Suppl. 5: S144-5
31. Tschudi MR, Criscione L, Lüscher TF. Effect of aging and hypertension on endothelial function of rat coronary arteries. J Hypertens 1991; 9 Suppl. 6: S164-5
32. Angus JA, Lew MJ. Interpretation of the acetylcholine test of endothelial dysfunction in hypertension. J Hypertens 1992; 10 Suppl. 7: S179-86
33. Cockcroft JR, Chowienczyk PJ, Benjamin N, et al. Preserved endothelium-dependent vasodilatation in patients with essential hypertension. New Engl J Med 1994; 330: 1036-40
34. Ferro CJ, Haynes WG, Hand MF, et al. Are the vascular endothelin and nitric oxide systems involved in the pathophysiology of essential hypertension. Eur J Clin Invest 1996; 26 Suppl. 1: A51
35. Huang A, Koller A. Both nitric oxide and prostaglandin-mediated responses are impaired in skeletal muscle arterioles of hypertensive rats. J Hypertens 1996; 14: 887-95
36. Panza JA, Casino PR, Kilcoyne CM, et al. Impaired endothelium-dependent vasodilatation in patients with essential hypertension: evidence that the abnormality is not at the muscarinic receptor level. J Am Coll Cardiol 1994; 23: 1610-6
37. Nava E, Noll G, Lüscher TF. Increased activity of constitutive nitric oxide synthase in cardiac endothelium in spontaneous hypertension. Circulation 1995; 91: 2310-3
38. Nava E, Lüscher TF. Endothelium-derived vasoactive factors in hypertension: nitric oxide and endothelin. J Hypertens 1995; 13 Suppl. 2: S39-48
39. Diedrich D, Yang Z, Bühler FR, et al. Impaired endothelium-dependent relaxations in hypertensive resistance arteries involve the cyclooxygenase pathway. Am J Physiol 1990; 258: H445-51
40. Nakazono K, Watanabe N, Matsuno K, et al. Does superoxide underlie the pathogenesis of hypertension? Proc Natl Acad Sci USA 1991; 88: 10045-8
41. Grunfeld S, Hamilton CA, Mesaros S, et al. Role of superoxide in the depressed nitric oxide production by the endothelium of genetically hypertensive rats. Hypertension 1995; 26: 854-7
42. Tschudi M, Mesaros S, Lüscher TF, et al. Direct in situ measurement of nitric oxide in mesenteric resistance arteries; increased decomposition by superoxide in hypertension. Hypertension 1995; 27: 32-5
43. Anderson TJ, Meredith IT, Yeung AC, et al. Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation 1996; 93: 1647-50
44. Stephens NG, Parsons A, Schofield PM, et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 347: 781-6
45. Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three different genes. Proc Natl Acad Sci USA 1989; 86: 2863-7
46. Bloch KD, Eddy RL, Shows TB, et al. cDNA cloning and chromosomal assigment of the gene encoding endothelin-3. J Biol Chem 1989; 264: 18156-61
47. Arai H, Hori H, Aramori I, et al. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990; 348: 730-2
48. Sakurai T, Yanagisawa M, Inoue I, et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990; 348: 732-5
49. Spokes RA, Ghatei MA, Bloom SR. Studies with endothelin-3 and endothelin-1 on rat blood pressure and isolated tissues: evidence for multiple endothelin receptor subtypes. J Cardiovasc Pharmacol 1989; 13 Suppl. 5: S191-2
50. A subtype. Br J Pharmacol 1995; 114: 1110-6
51. Tschudi MR, Lüscher TF. Characterisation of contractile endothelin and angiotensin receptors in human resistance arteries: evidence for two endothelin and one angiotensin receptor. Biochem Biophys Res Commun 1994; 204: 685-90
52. B receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. Circulation 1995; 92: 357-63
53. Takayanagi R, Kitazumi K, Takashi C, et al. Presence of a nonselective type of endothelin receptor on vascular endothelium and its linkage to vasodilatation. FEBS Lett 1991; 282: 103-6
54. A receptors in humans? Trends Pharmacol Sci 1994; 15: 9-11
55. Douglas S, Gellai M, Ezekiel M, et al. BQ-123, a selective endothelin subtype A-receptor antagonist, lowers blood pressure in different rat models of hypertension. J Hypertens 1994; 12: 561-7
56. Li JS, Larivière R, Schiffrin EL. Effect of a nonselective endothelin antagonist on vascular remodelling in deoxycorticosterone acetate-salt hypertensive rats: evidence for a role of endothelin in vascular hypertrophy. Hypertension 1994; 24: 183-8
57. Yang Z, Richard V, von Segresser L, et al. Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries: a new mechanism for vasospasm? Circulation 1990; 82: 188-95
58. Kohno M, Murakawa K, Horio T, et al. Plasma immunoreactive endothelin-1 in experimental malignant hypertension. Hypertension 1991; 18: 93-100
59. Wagner OF, Christ G, Wojta J, et al. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 1992; 267: 16066-8
60. Larivière R, Thibault G, Schriffin E. Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not spontaneously hypertensive rats. Hypertension 1993; 21: 294-300
61. Clozel M. Endothelin sensitivity and receptor binding in the aorta of spontaneously hypertensive rats. J Hypertens 1989; 7: 913-7
62. Dohi Y, Lüscher TF. Endothelin-1 in hypertensive resistance arteries: intraluminal and extraluminal dysfunction. Hypertension 1991; 18: 543-9
63. Roberts-Thomson P, McRitchie R, Chalmers R. Experimental hypertension produces diverse changes in the regional vascular responses to endothelin-1 in the rabbit and the rat. J Hypertens 1994; 12: 1225-34
64. Haynes WG, Hand MF, Johnstone H, et al. Direct and sympathetically mediated venoconstriction in essential hypertension. J Clin Invest 1994; 94: 1359-64
65. Yoshida M, Nonoguchi H, Owada A, et al. Three cases of malignant hypertension: the roles of endothelin-1 and the reninangiotensin-aldosterone system. Clin Nephrol 1994; 42: 295-9
66. Florijin K, Derkx F, Visser W, et al. Plasma immunoreactive endothelin-1 in pregnant women with and without pre-eclampsia. J Cardiovasc Pharmacol 1991; 17 Suppl. 7: S446-8
67. Yokokawa K, Tahara H, Kohno M, et al. Hypertension associated with endothelin secreting malignant haemangio-endothelioma. Ann Int Med 1991; 114: 213-5
68. Schiffrin EL, Deng LY, Larochelle P. Blunted effects of endothelin upon small subcutaneous resistance arteries of mild essential hypertensive patients. J Hypertens 1992; 10: 437-44
69. Schiffrin EL, Deng LY, Sventek P, et al. Expression of endothelin-1 gene in small arteries in human essential hypertension. J Hypertens 1996; 14 Suppl. 1: S290
70. Noll G, Wenzel RR, Sehneider M, et al. Increased activation of sympathetic nervous system and endothelin by mental stress in normotensive offspring of hypertensive parents. Circulation 1996; 93: 866-9
71. Omlamd T, Lie R, Aakvaag A, et al. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994; 89: 1573-9
72. Lerman A, Edwards B, Hallett J, et al. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl Med J 1991; 325: 997-1001
73. Winkles J, Alberts G, Brogi E, et al. Endothelin-1 binding and endothelin immunoreactivity in normal and atherosclerotic human arteries. Biochem Biophys Res Commun 1993; 191: 1081-8
74. Zeiher MA, Goebel H, Schachinger V, et al. Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque. Circulation 1995; 91: 941-7
75. Lüscher TF, Yang Z. Calcium antagonists and ACE inhibitors: effect on endothelium and vascular smooth muscle. Drugs 1993; 46 Suppl. 2: 121-32
76. Johns A, Freay AD, Adams DJ, et al. The role of calcium in the activation of endothelial cells. J Cardiovasc Pharmacol 1988; 12 Suppl. 5: 119-23
77. Erne P, Bolli P, Burgisser E, et al. Correlation of platelet calcium with blood pressure: effect of antihypertensive therapy [letter]. N Engl J Med 1984; 310: 1084
78. Folkow B, Hallback M, Jones JV, et al. Dependence on external calcium for the noradrenaline contractility of the resistance vessels in spontaneously hypertensive rats. Acta Physiol Scand 1977; 101: 84-97
79. Himmel HM, Whorton AR, Strauss HC. Intracellular calcium, currents and stimulus-response coupling in endothelial cells. Hypertension 1993; 21: 112-27
80. Yang ZH, Von SL, Bauer E, et al. Different activation of the endothelial L-arginine and cyclooxygenase pathway in the human internal mammary artery and saphenous vein. Circ Res 1991; 68: 52-60
81. Goerre S, Wenk M, Bärtsch P, et al. Endothelin-1 in pulmonary hypertension associated with high altitude exposure. Circulation 1995; 91: 359-64
82. Goto K, Kasuya Z, Matsuki N, et al. Endothelin activates the dihydropyridine-sensitive, voltage-dependent calcium channel in vascular smooth muscle. Proc Natl Acad Sci USA 1989; 86: 3915-8
83. Clarke JG, Benjamin N, Larkin SW, et al. Endothelin is a potent long-lasting vasoconstrictor in men. Am J Physiol 1989; 257: H2033-5
84. Clozel M, Kuhn H, Hefti F. Effects of angiotensin converting enzyme inhibitors and of hydralazine on endothelial function in hypertensive rats. Hypertension 1990; 16: 532-40
85. 2+ channel inhibitor RO 40-5967 potentiates the endothelium-dependent relaxations in the aorta of the hypertensive salt sensitive Dahl rat. Blood Pressure 1994; 3: 193-6
86. Hirooka Y, Imaizumi T, Masaki H, et al. Captopril improves impaired endothelium-dependent vasodilatation in hypertensive patients. Hypertension 1992; 20: 175-80
87. Ghiadoni L, Taddei S, Magagna A, et al. Effect of lacidipine on endothelial function in hypertensive patients. Am J Hypertens 1996; 9: 155A
88. Perticone F, Ceravolo R, Maio R, et al. Effects of long term isradipine treatment on endothelial vasodilation in hypertensives. Am J Hypertens 1996; 9: 165A
89. Schiffrin EL, Deng LY, Larochelle P. Effects of a β-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension. Hypertension 1994; 23: 83-91
90. Taddei S, Virdis MP, Arzilli F, et al. Endothelium-dependent forearm vasodilatation is reduced in normotensive subjects with familial history of hypertension. J Cardiovasc Pharmacol 1992; 20 Suppl. 12: S193-5
91. Willis AL, Nagel B, Churchill V, et al. Antiatherosclerotic effects of nicardipine and nifedipine in cholesterol-fed rabbits. Arteriosclerosis 1985; 5: 250-5
92. Yamada Y, Furui H, Furumichi T, et al. Inhibitory effects of endothelial cells and calcium channel blockers on platelet aggregation. Jpn Heart J 1990; 31: 201-15
93. Mentley RK, Brezinski ME, Tse E, et al. Cardioprotective actions of nisoldipine in postperfusion myocardial ischaemia. Am Heart J 1988; 115: 948-54
94. Yang Z, Noll G, Lüscher TF. Calcium antagonists inhibit proliferation of human coronary artery smooth muscle cells in response to pulsatile stretch and platelet-derived growth factor. Circulation 1993; 88: 832-6
95. Steinberg D, Parthasarathy S, Carew TE, et al. Beyond cholesterol; modification of low-density lipoproteins that increase its atherogenicity. N Engl J Med 1989; 320: 915-24
96. Mak IT, Boehme P, Weglicki WB. Antioxidant effects of calcium channel blockers against free radical injury in endothelial cells. Correlation of protection with preservation of glutathione levels. Circ Res 1992; 70: 1099-103
97. Lichtlen PR, Hugenholtz P, Rafflenbeul W, et al. Retardation of the angiographic progression of coronary artery disease in man by the calcium channel blocker nifedipine. Lancet 1990; 335: 1109-13
98. Waters D, Lesperance J, Francetich M, et al. A controlled trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation 1990; 82: 1940-53
99. Brogden RN, Sarkin EM. Isradipine: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension. Drugs 1995; 49: 618-49
100. Elliot HL. Endothelial dysfunction: clinical applicability of calcium antagonist drugs. In: Lüscher TF, editor. The endothelium in cardiovascular disease. Berlin: Springer-Verlag, 1995: 148-56
101. Zanchetti A, on behalf of the Italian Nifedipine GITS Study Group. The 24-hour efficacy of a new once-daily formulation of nifedipine. Drugs 1994; 48 Suppl. 1: 23-31
102. Brown MJ, Castaigne A, Mancia G, et al. Hypertension intervention trial in high risk patients: a comparison of the effects of nifedipine GITS and hydrochlorothiazide/amiloride on cardiovascular and cerebrovascular morbidity and mortality (INSIGHT) [Abstract no. 112]. Seventh European Meeting on Hypertension; 1995 Jun 9: Milan: 28